Immunotherapy before surgery for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (PDAC) that can be surgically removed
- You are in good overall health (able to do daily activities without help or with light work)
- You weigh at least 35 kg (about 77 lbs)
- You have not had immunotherapy or certain other cancer treatments in the past
- You do not have an active autoimmune disease or serious heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
This Phase 2 trial tests a combination of immunotherapy (sintilimab) and chemotherapy (nab-paclitaxel and gemcitabine) given before surgery and again after surgery for pancreatic cancer that can be removed (or close to removable). It aims to improve outcomes by shrinking the tumor before the operation and reducing the chance of return after surgery.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.